---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-260305"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T16:35:48.904755+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx prices $300M public offering of common stock and pre-funded warrants

## Summary
- 8,333,334 shares at $30.00/share plus 1,666,722 pre-funded warrants at $29.9990 each.
- Underwriters exercised option for 1,500,000 additional shares; total net proceeds ~$326.1M.
- Offering expected to close October 23, 2023.
- J.P. Morgan, Goldman Sachs, BofA Securities, Cowen acted as underwriters.

## SEC filing metadata
- accession: 0001193125-23-260305
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000119312523260305/0001193125-23-260305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000119312523260305/d524225d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-260305
- JSON: https://secwatch.observer/filing/0001193125-23-260305.json
- Plain text: https://secwatch.observer/filing/0001193125-23-260305.txt

## Key facts
- Material Agreements
  Ultragenyx Pharmaceutical Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC (effective 2023-10-18).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC
  - Effective: 2023-10-18
  source text: On October 18, 2023, Ultragenyx Pharmaceutical Inc. (“ Ultragenyx ” or the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC (the “ Underwriters ”), providing for the offer and sale in an underwritten public offering (the “ Offering ”) of 8,333,334 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and in lieu of Common Stock to certain investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 1,666,722 shares of Common Stock (the “ Warrant Shares ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000119312523260305/0001193125-23-260305-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.